ERBB2 and breast cancer: Although it is accepted that HER2-targeted therapy does not respond to HER2-negative breast cancer cells [4], our data indicated that trastuzumab treatment sensitized the radioresistant phenotype of CD44+/CD24–/low MCF7 cells.